| Literature DB >> 27956542 |
Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W Deininger, Aaron T Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B Klisovic, Patricia Kropf, Sanjay R Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A Pollyea, Raajit Rampal, Lindsay A M Rein, Bart Scott, David S Snyder, Brady L Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S Wang, Mary Anne Bergman, Kristina M Gregory, Hema Sundar.
Abstract
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27956542 DOI： 10.6004/jnccn.2016.0169
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908